Danaher Co. (NYSE:DHR) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC decreased its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 68.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,803 shares of the conglomerate's stock after selling 49,603 shares during the period. Bryn Mawr Capital Management LLC's holdings in Danaher were worth $5,234,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in DHR. Kentucky Retirement Systems Insurance Trust Fund lifted its position in Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate's stock valued at $4,874,000 after purchasing an additional 2,202 shares during the period. Fort Pitt Capital Group LLC lifted its position in Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate's stock valued at $66,194,000 after purchasing an additional 7,421 shares during the period. ORG Partners LLC lifted its position in Danaher by 1,212.8% in the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate's stock valued at $636,000 after purchasing an additional 2,559 shares during the period. Harvest Portfolios Group Inc. lifted its position in Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate's stock valued at $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Generate Investment Management Ltd acquired a new stake in Danaher in the fourth quarter valued at about $8,044,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Up 1.4 %

Shares of DHR traded up $2.98 during mid-day trading on Friday, reaching $210.93. The company had a trading volume of 3,938,105 shares, compared to its average volume of 4,498,829. The stock has a market cap of $152.35 billion, a price-to-earnings ratio of 39.97, a price-to-earnings-growth ratio of 2.61 and a beta of 0.83. The firm has a fifty day simple moving average of $227.21 and a 200-day simple moving average of $247.52. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts' consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a positive change from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio (DPR) is 20.45%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DHR shares. Citigroup dropped their target price on shares of Danaher from $285.00 to $265.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Scotiabank started coverage on shares of Danaher in a report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a report on Thursday, January 30th. Jefferies Financial Group dropped their target price on shares of Danaher from $285.00 to $260.00 and set a "buy" rating for the company in a report on Wednesday, January 29th. Finally, Barclays dropped their target price on shares of Danaher from $275.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $278.00.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.